Science Explorer Interactive view Map
Company · San Diego · United States

aTyr Pharma (United States)

atyrpharma.comROR OpenAlex
Research works
42
▲ 169% vs 2013–17
Citations
829
19.8 per fractional work
Top-10% rate
9.1%
record average 16.5%
Open access
24%
world 28%

Not ranked overall: aTyr Pharma (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.03× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 4.52× its world share, 4 worksBiochemistry, Geneti…Immunology and Microbiology: 6.33× its world share, 1 worksImmunology and Micro…Neuroscience: 0.93× its world share, 0 worksNeuroscienceHealth Professions: 0.73× its world share, 0 worksHealth ProfessionsMedicine: 3.43× its world share, 12 worksMedicine1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 6.3×. Every wedge is a field page.

Which keywords describe research at aTyr Pharma (United States)?

By fractional works in all years, weighted toward what it does more of than the world: Diagnosis, Epithelial-Mesenchymal Transition, Management, Fibrosis, TGF-ß, Interstitial Lung Disease, Imaging and Idiopathic Pulmonary Fibrosis.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 38 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 38 words, with their numbers
  1. Diagnosis4▲ 9.2×9 topics
  2. Epithelial-Mesenchymal Transition4▲ 107×2 topics
  3. Management4▲ 11×5 topics
  4. Fibrosis4▲ 44×3 topics
  5. Inflammation4▲ 3.7×17 topics
  6. TGF-ß3▲ 48×3 topics
  7. Imaging3▲ 22×2 topics
  8. Interstitial Lung Disease3▲ 143×2 topics
  9. Cardiac3▲ 438×1 topic
  10. Idiopathic Pulmonary Fibrosis3▲ 197×1 topic
  11. Myofibroblast3▲ 197×1 topic
  12. Sarcoidosis3▲ 438×1 topic
  13. Cancer3▲ 5.2×13 topics
  14. VEGF3▲ 200×1 topic
  15. endothelial progenitor cells3▲ 200×1 topic
  16. Tumor Microenvironment3▲ 18×5 topics
  17. Monoclonal Antibodies2▲ 40×3 topics
  18. Cancer Progression2▲ 24×2 topics
  19. Glycosylation2▲ 25×3 topics
  20. RNA methylation2▲ 65×1 topic
  21. m6A-seq2▲ 65×1 topic
  22. Ribosome2▲ 51×1 topic
  23. Therapeutic Antibodies2▲ 38×2 topics
  24. Translation2▲ 25×1 topic
  25. Epidemiology2◆ 1.06×16 topics
  26. HIF-12▲ 61×1 topic
  27. Warburg Effect2▲ 61×1 topic
  28. Treatment2▲ 3.1×10 topics
  29. Antibody Engineering2▲ 37×1 topic
  30. Fc Receptors2▲ 37×1 topic
  31. Genetic Mutations2▲ 7.2×7 topics
  32. Alternative Splicing1▲ 52×1 topic
  33. RNA-Binding Proteins1▲ 52×1 topic
  34. Epigenetic Regulation1▲ 12×3 topics
  35. Metastasis1▲ 7.7×3 topics
  36. Receptor tyrosine kinases1▲ 60×2 topics
  37. Ehlers-Danlos Syndrome1▲ 94×1 topic
  38. Marfan Syndrome1▲ 94×1 topic

Which research topics does aTyr Pharma (United States) publish most on?

By volume in 2022–2025: Sarcoidosis and Beryllium Toxicity Research, Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Angiogenesis and VEGF in Cancer and Connective tissue disorders research.

Sarcoidosis and Berylliu…3Sarcoidosis and Beryllium Toxicity Research: 3 fractional worksInterstitial Lung Diseas…2Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis: 2 fractional worksAngiogenesis and VEGF in Cancer: 1 fractional worksConnective tissue disorders research: 1 fractional worksCancer, Hypoxia, and Metabolism: 1 fractional worksCancer Treatment and Pha…1Cancer Treatment and Pharmacology: 1 fractional worksLymphatic System and Diseases: 0 fractional worksCancer Cells and Metastasis: 0 fractional worksBacillus and Francisella bacterial research: 0 fractional worksHER2/EGFR in Cancer Research: 0 fractional works
PhysiologyPulmonary and Respiratory MedicineMolecular BiologyGenetics2 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Sarcoidosis and Beryllium Toxicity Research Physiology 3 works
  2. 2 Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Pulmonary and Respiratory Medicine 2 works
  3. 3 Angiogenesis and VEGF in Cancer Molecular Biology 1 works
  4. 4 Connective tissue disorders research Genetics 1 works
  5. 5 Cancer, Hypoxia, and Metabolism Cancer Research 1 works
  6. 6 Cancer Treatment and Pharmacology Oncology 1 works
  7. 7 Lymphatic System and Diseases Oncology 0 works
  8. 8 Cancer Cells and Metastasis Oncology 0 works
  9. 9 Bacillus and Francisella bacterial research Molecular Biology 0 works
  10. 10 HER2/EGFR in Cancer Research Oncology 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available23.5%not open76.5%

World: 28% of research is openly available.

with international co-authors22.4%domestic only77.6%

World: 19% is written across borders.

How has aTyr Pharma (United States)'s research output changed?

Output in 2018–2022 was 169% higher than in 2013–2017.

20002005201020152020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in San Diego

All research institutions in San Diego

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.